TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 2B 4B 6B Q3 '21: 3.9B Q4 '21: 4.1B Q1 '22: 3.7B Q2 '22: 3.8B Q3 '22: 3.6B Q4 '22: 3.9B Q1 '23: 3.7B Q2 '23: 3.9B Q3 '23: 3.9B Q4 '23: 4.5B Q1 '24: 3.8B Q2 '24: 4.2B Q3 '24: 4.3B Q4 '24: 4.2B Q1 '25: 3.9B Q2 '25: 4.2B Q3 '25: 4.5B Q4 '25: 4.7B Q1 '26: 4B Q2 '26: 4.1B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 1B 2B 3B Q3 '21: 1.8B Q4 '21: 2B Q1 '22: 1.7B Q2 '22: 1.8B Q3 '22: 1.7B Q4 '22: 1.8B Q1 '23: 1.6B Q2 '23: 1.8B Q3 '23: 1.9B Q4 '23: 2.4B Q1 '24: 1.8B Q2 '24: 2B Q3 '24: 2.1B Q4 '24: 2.1B Q1 '25: 1.9B Q2 '25: 2.1B Q3 '25: 2.3B Q4 '25: 2.7B Q1 '26: 2B Q2 '26: 2.2B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-1.1B -700M -350M 0 350M 700M 1.1B Q3 '21: 623M Q4 '21: 78M Q1 '22: -713M Q2 '22: -949M Q3 '22: 419M Q4 '22: -940M Q1 '23: -13M Q2 '23: -654M Q3 '23: 344M Q4 '23: 756M Q1 '24: -218M Q2 '24: -5M Q3 '24: -51M Q4 '24: -29M Q1 '25: 519M Q2 '25: 455M Q3 '25: 882M Q4 '25: 300M Q1 '26: 652M Q2 '26: -231M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-1.5B -1B -500M 0 500M 1B 1.5B Q2 '21: 207M Q3 '21: 292M Q1 '22: -955M Q2 '22: -232M Q3 '22: 56M Q4 '22: -1.3B Q1 '23: -220M Q2 '23: -872M Q3 '23: 69M Q4 '23: 464M Q1 '24: -139M Q2 '24: -846M Q3 '24: -437M Q4 '24: -217M Q1 '25: 214M Q2 '25: 282M Q3 '25: 433M Q4 '25: 480M Q1 '26: 369M Q2 '26: -576M Q3 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 800M 1.6B 2.4B Q3 '21: 2.1B Q4 '21: 2B Q1 '22: 1.9B Q2 '22: 2B Q3 '22: 1.9B Q4 '22: 2.1B Q1 '23: 2.1B Q2 '23: 2.1B Q3 '23: 2B Q4 '23: 2B Q1 '24: 2B Q2 '24: 2.1B Q3 '24: 2.2B Q4 '24: 2.1B Q1 '25: 2B Q2 '25: 2.1B Q3 '25: 2.2B Q4 '25: 2.1B Q1 '26: 2B Q2 '26: 2B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-500M 0 500M 1B 1.5B Q3 '21: 529M Q4 '21: 456M Q1 '22: -49M Q2 '22: 123M Q3 '22: 543M Q4 '22: 973M Q1 '23: -145M Q2 '23: 324M Q3 '23: 5M Q4 '23: 1.2B Q1 '24: -124M Q2 '24: 103M Q3 '24: 693M Q4 '24: 575M Q1 '25: -105M Q2 '25: 227M Q3 '25: 369M Q4 '25: 1.2B Q1 '26: -40M Q2 '26: 411M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-400M 0 400M 800M 1.2B Q3 '21: 383M Q4 '21: 303M Q1 '22: -206M Q2 '22: -4M Q3 '22: 421M Q4 '22: 831M Q1 '23: -284M Q2 '23: 205M Q3 '23: -144M Q4 '23: 1.1B Q1 '24: -248M Q2 '24: 6M Q3 '24: 545M Q4 '24: 446M Q1 '25: -232M Q2 '25: 131M Q3 '25: 233M Q4 '25: 1B Q1 '26: -208M Q2 '26: 307M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 500M 1B 1.5B Q1 '20: 1.1B Q2 '20: 1.1B Q3 '20: 1.1B Q1 '21: 1.1B Q2 '21: 1.1B Q3 '21: 1.1B Q1 '22: 1.1B Q2 '22: 1.1B Q3 '22: 1.1B Q1 '23: 1.1B Q2 '23: 1.1B Q3 '23: 1.1B Q1 '24: 1.1B Q2 '24: 1.1B Q3 '24: 1.1B Q1 '25: 1.2B Q2 '25: 1.2B Q3 '25: 1.2B Q1 '26: 1.2B Q2 '26: 1.2B Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '20: -3.68 Q4 '20: -3.64 Q1 '21: -3.63 Q2 '21: -3.57 Q3 '21: 0.66 Q4 '22: -2.19 Q1 '23: -1.53 Q2 '23: -2.10 Q3 '23: -2.09 Q4 '23: -0.50 Q1 '24: -0.42 Q2 '24: -0.39 Q3 '24: -0.84 Q4 '24: -1.45 Q1 '25: -1.15 Q2 '25: -0.16 Q3 '25: 0.60 Q4 '25: 1.20 Q1 '26: 1.33 Q2 '26: 0.60 Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.